Skip to content

Effect of percutaneous auricular vagus nerve stimulation on gastrointestinal function in patients with gastric cancer after surgery

Study on the effect of percutaneous vagus nerve stimulation on gastrointestinal function in patients after gastric cancer surgery

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500102789
Enrollment
Unknown
Registered
2025-05-20
Start date
2025-06-01
Completion date
Unknown
Last updated
2025-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

postoperative ileus after Radical Gastrectomy

Interventions

Transcutaneous auricular vagus nerve stimulation group:Accept bilateral TEAS auricular internal organ area/auricle area, with normal instrumentation for stimulation. Interventions are carried out at 2
Sham Transcutaneous Vagus Nerve Stimulation Group:Subjects assigned to the ShamTEAS auricular acupoint group will receive sham stimulation, with the stimulation device being a placebo stimulator. The

Sponsors

Qilu Hospital of Shandong University(Qingdao)
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) Pathologically diagnosed gastric cancer (stage I-III), American Society of Anesthesiologists (ASA) grade I-III, and planned to undergo elective laparoscopic gastrectomy; (2) Age: 18-75 years old, gender is not limited; (3) Patients who voluntarily or their families agree to participate in the trial and sign the informed consent form for the trial.

Exclusion criteria

Exclusion criteria: 1. History of previous abdominal surgery; 2. Plan for palliative resection, emergency surgery, or combined resection of other organs (such as liver, pancreas); 3. Discovery of serious complications intraoperatively necessitating conversion to open surgery (such as massive bleeding, anastomotic leak); 4. Presence of non-cancerous gastric lesions (confirmed by postoperative pathology); 5. Serious postoperative complications occurring during the study requiring a second surgery; 6. Comorbidities of severe cardiac, hepatic, renal diseases, or mental illness; 7. Local skin infections preventing the placement of electrodes; 8. Patients with permanent cardiac pacemakers installed; 9. Pregnant or breastfeeding women; 10. Individuals unable to maintain a resting state (such as those with epilepsy, Parkinson's disease, etc.); 11. Patients or their family members unwilling to sign the informed consent form for the trial.

Design outcomes

Primary

MeasureTime frame
First exhaust time;

Secondary

MeasureTime frame
First bowel movement time;The incidence of POI extension;Timing of water intake ;Liquid diet tolerance time;Solid food tolerance time;Number of episodes of nausea, vomiting, and bloating;Severity of postoperative pain;First out-of-bed time;First independent walking time;Length of postoperative hospital stay;Nutritional Risk Screening (NRS-2002);Quality of Life Questionnaire;Adverse events (AEs);Severe complications;

Countries

China

Contacts

Public ContactFeng Li

Qilu Hospital of Shandong University(Qingdao)

201062000137@sdu.edu.cn+86 185 6181 3993

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026